Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cavazzoni

Showing results (201-210 of 308) with videos related to

Pageof 31
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 31, 2013
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitorsFederica Vacondio, Caterina Carmi, Elena Galvani, et al.
International Journal of Molecular Sciences|July 26, 2020
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer CellsMara Bonelli, Rita Terenziani, Silvia Zoppi, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 29, 2018
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cellsDaniele Cretella, Andrea Ravelli, Claudia Fumarola, et al.
Journal of Thoracic Disease|March 7, 2018
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesotheliomaFabio Sonvico, Stefano Barbieri, Paolo Colombo, et al.
The American Journal of Psychiatry|October 4, 2005
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophreniaAlan Breier, Paul H Berg, Jogin H Thakore, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 15, 2025
Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cellsDaniele Cretella, Andrea Ravelli, Claudia Fumarola, et al.
Transplantation|February 29, 2024
Transmission and Non-transmission of Melanoma From Deceased Solid Organ Donors to Transplant Recipients: Risks and Missed OpportunitiesBrenda Maria Rosales, James Hedley, Nicole De La Mata, et al.
Breast Cancer Research and Treatment|January 24, 2026
Correction: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signalingClaudia Fumarola, Cristina Caffarra, Silvia La Monica, et al.
The Journal of Clinical Psychiatry|July 20, 2006
A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementiaLudmila A Kryzhanovskaya, Dilip V Jeste, Carrie A Young, et al.
Transplantation|July 26, 2023
MHC Tetramers Specifically Identify High- and Low-avidity Donor-specific B Cells in Transplantation Tolerance and RejectionSamarth S Durgam, Stella H W Khiew, Ismail Sayin, et al.
Pageof 31

Showing results (201-210 of 308) with videos related to

Sort By:
Pageof 31
Bioorganic & Medicinal Chemistry Letters|August 31, 2013
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitorsFederica Vacondio, Caterina Carmi, Elena Galvani, et al.
International Journal of Molecular Sciences|July 26, 2020
Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer CellsMara Bonelli, Rita Terenziani, Silvia Zoppi, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 29, 2018
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cellsDaniele Cretella, Andrea Ravelli, Claudia Fumarola, et al.
Journal of Thoracic Disease|March 7, 2018
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesotheliomaFabio Sonvico, Stefano Barbieri, Paolo Colombo, et al.
The American Journal of Psychiatry|October 4, 2005
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophreniaAlan Breier, Paul H Berg, Jogin H Thakore, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 15, 2025
Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cellsDaniele Cretella, Andrea Ravelli, Claudia Fumarola, et al.
Transplantation|February 29, 2024
Transmission and Non-transmission of Melanoma From Deceased Solid Organ Donors to Transplant Recipients: Risks and Missed OpportunitiesBrenda Maria Rosales, James Hedley, Nicole De La Mata, et al.
Breast Cancer Research and Treatment|January 24, 2026
Correction: Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signalingClaudia Fumarola, Cristina Caffarra, Silvia La Monica, et al.
The Journal of Clinical Psychiatry|July 20, 2006
A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementiaLudmila A Kryzhanovskaya, Dilip V Jeste, Carrie A Young, et al.
Transplantation|July 26, 2023
MHC Tetramers Specifically Identify High- and Low-avidity Donor-specific B Cells in Transplantation Tolerance and RejectionSamarth S Durgam, Stella H W Khiew, Ismail Sayin, et al.
Pageof 31